Literature DB >> 29497164

The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption.

M E Sloan1, T D Klepp2, J L Gowin1, J E Swan1, H Sun2, B L Stangl1, V A Ramchandani3.   

Abstract

The endogenous opioid system may be involved in the development and maintenance of alcohol use disorder (AUD) and is a target for existing AUD pharmacotherapies. A functional polymorphism of the mu-opioid receptor gene (OPRM1 A118G, rs1799971) may alter the risk of developing AUD. Human laboratory studies have demonstrated that minor allele carriers self-administer more alcohol, show greater sensitivity to alcohol's effects, and exhibit increased alcohol-induced dopamine release. On the other hand, large genome-wide association studies and meta-analyses of candidate gene studies have not found an association between this genotype and alcohol dependence diagnosis. Given this discrepancy, the present study sought to verify whether OPRM1 A118G was associated with alcohol self-administration, subjective response to alcohol, and craving in a sample of 106 social drinkers of European ancestry who completed an intravenous alcohol self-administration session. We found no relationship between OPRM1 rs1799971 genotype and subjective response to alcohol or craving. OPRM1 genotype was not associated with total alcohol exposure or likelihood of attaining a binge-level exposure (80 mg%) during the intravenous alcohol self-administration session. Analysis of 90-day Timeline Followback interview data in a larger sample of 965 participants of European ancestry found no relationship between OPRM1 genotype and alcohol consumption in either alcohol dependent or non-dependent participants. These findings suggest that there may not be an association between OPRM1 rs1799971 genotype and alcohol consumption or sensitivity in individuals of European ancestry.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29497164      PMCID: PMC5983535          DOI: 10.1038/s41386-017-0002-8

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  49 in total

1.  Vulnerability for Alcohol Use Disorder and Rate of Alcohol Consumption.

Authors:  Joshua L Gowin; Matthew E Sloan; Bethany L Stangl; Vatsalya Vatsalya; Vijay A Ramchandani
Journal:  Am J Psychiatry       Date:  2017-08-04       Impact factor: 18.112

2.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

3.  Spurious genetic associations.

Authors:  Patrick F Sullivan
Journal:  Biol Psychiatry       Date:  2007-03-08       Impact factor: 13.382

4.  Addictions biology: haplotype-based analysis for 130 candidate genes on a single array.

Authors:  Colin A Hodgkinson; Qiaoping Yuan; Ke Xu; Pei-Hong Shen; Elizabeth Heinz; Elizabeth A Lobos; Elizabeth B Binder; Joe Cubells; Cindy L Ehlers; Joel Gelernter; John Mann; Brien Riley; Alec Roy; Boris Tabakoff; Richard D Todd; Zhifeng Zhou; David Goldman
Journal:  Alcohol Alcohol       Date:  2008-05-12       Impact factor: 2.826

5.  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

Authors:  J T Sullivan; K Sykora; J Schneiderman; C A Naranjo; E M Sellers
Journal:  Br J Addict       Date:  1989-11

6.  The Self-Rating of the Effects of alcohol (SRE) form as a retrospective measure of the risk for alcoholism.

Authors:  M A Schuckit; T L Smith; J E Tipp
Journal:  Addiction       Date:  1997-08       Impact factor: 6.526

7.  Intravenous ethanol infusion decreases human cortical γ-aminobutyric acid and N-acetylaspartate as measured with proton magnetic resonance spectroscopy at 4 tesla.

Authors:  Rosane Gomez; Kevin L Behar; June Watzl; Stuart A Weinzimer; Barbara Gulanski; Gerard Sanacora; Julia Koretski; Elizabeth Guidone; Lihong Jiang; Ismene L Petrakis; Brian Pittman; John H Krystal; Graeme F Mason
Journal:  Biol Psychiatry       Date:  2011-08-19       Impact factor: 13.382

8.  Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.

Authors:  Raymond F Anton; Konstantin K Voronin; Patrick K Randall; Hugh Myrick; Abraham Tiffany
Journal:  Alcohol Clin Exp Res       Date:  2012-05-02       Impact factor: 3.455

9.  A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Alcohol Clin Exp Res       Date:  2004-12       Impact factor: 3.455

10.  An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.

Authors:  Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman
Journal:  Arch Gen Psychiatry       Date:  2008-02
View more
  12 in total

1.  Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry.

Authors:  Dina Popova; Nidhi Desai; Julie A Blendy; Zhiping P Pang
Journal:  J Neurosci       Date:  2019-05-20       Impact factor: 6.167

2.  Differential sensitivity of human neurons carrying μ opioid receptor (MOR) N40D variants in response to ethanol.

Authors:  Matthew S Scarnati; Andrew J Boreland; Marisa Joel; Ronald P Hart; Zhiping P Pang
Journal:  Alcohol       Date:  2020-06-17       Impact factor: 2.405

Review 3.  Post-translational Modifications of Opioid Receptors.

Authors:  Mariana Lemos Duarte; Lakshmi A Devi
Journal:  Trends Neurosci       Date:  2020-04-16       Impact factor: 13.837

4.  The effects of acute alcohol administration on circulating endocannabinoid levels in humans.

Authors:  Matthew E Sloan; Caroline W Grant; Bethany L Stangl; Timothy D Klepp; Honoree W Brewton; Resat Cinar; George Kunos; Vijay A Ramchandani
Journal:  Addict Biol       Date:  2022-09       Impact factor: 4.093

5.  Elevated stearoyl-CoA desaturase 1 activity is associated with alcohol-associated liver disease.

Authors:  T D Klepp; M E Sloan; Soundarya Soundararajan; C E Ramsden; R Cinar; M L Schwandt; N Diazgranados; V Vatsalya; V A Ramchandani
Journal:  Alcohol       Date:  2022-04-19       Impact factor: 2.558

6.  Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.

Authors:  Emily E Hartwell; Richard Feinn; Paige E Morris; Joel Gelernter; John Krystal; Albert J Arias; Michaela Hoffman; Ismene Petrakis; Ralitza Gueorguieva; Joseph P Schacht; David Oslin; Raymond F Anton; Henry R Kranzler
Journal:  Addiction       Date:  2020-02-11       Impact factor: 6.526

7.  High-risk social drinkers and heavy drinkers display similar rates of alcohol consumption.

Authors:  Matthew E Sloan; Joshua L Gowin; Roshni Janakiraman; Corbin D Ester; Joel Stoddard; Bethany Stangl; Vijay A Ramchandani
Journal:  Addict Biol       Date:  2019-03-01       Impact factor: 4.093

8.  Alcohol Cue-Induced Ventral Striatum Activity Predicts Subsequent Alcohol Self-Administration.

Authors:  Aaron C Lim; ReJoyce Green; Erica N Grodin; Alexandra Venegas; Lindsay R Meredith; Suzanna Donato; Elizabeth Burnette; Lara A Ray
Journal:  Alcohol Clin Exp Res       Date:  2020-05-14       Impact factor: 3.928

Review 9.  To Infuse or Ingest in Human Laboratory Alcohol Research.

Authors:  Melissa A Cyders; Martin H Plawecki; William Corbin; Andrea King; Denis M McCarthy; Vijay A Ramchandani; Jessica Weafer; Sean J O'Connor
Journal:  Alcohol Clin Exp Res       Date:  2020-03-15       Impact factor: 3.455

10.  Association of the OPRM1 A118G polymorphism and Pavlovian-to-instrumental transfer: Clinical relevance for alcohol dependence.

Authors:  Miriam Sebold; Maria Garbusow; Deniz Cerci; Ke Chen; Christian Sommer; Quentin Jm Huys; Stephan Nebe; Michael Rapp; Ilya M Veer; Ulrich S Zimmermann; Michael N Smolka; Henrik Walter; Andreas Heinz; Eva Friedel
Journal:  J Psychopharmacol       Date:  2021-03-16       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.